Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat conditions. The Company's commercial products are the PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is also developing PROPEL mini for use in frontal sinus surgery and is conducting clinical trials to evaluate two products, RESOLVE and NOVA, for treatment of patients in the physician's office. The Company is developing the RESOLVE steroid releasing implant as an alternative treatment option for patients who are candidates for revision surgery that can be placed in the physician office setting during a routine visit. The Company is also developing NOVA, a steroid releasing implant designed to fit the openings of the frontal and maxillary sinuses following ostial dilation using balloon sinuplasty.